Search Results - "Ejskjaer, N"

Can the Routine Use of Patient-Reported Outcome Measures Improve the Delivery of Person-Centered Diabetes Care? A Review of Recent Developments and a Case Study by Skovlund, Soren E., Lichtenberg, TH, Hessler, D., Ejskjaer, N.

“…Purpose of Review In recent years, the recommendation for and use of patient-reported outcome measures (PROMs) in routine diabetes care has significantly…”
Get full text

Accelerated atrophy of lower leg and foot muscles--a follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging (MRI) by Andreassen, C. S, Jakobsen, J, Ringgaard, S, Ejskjaer, N, Andersen, H

“…Aims/hypothesis The aim of the study was to determine the loss of muscle volume in the lower leg and foot in long-term diabetic patients in relation to the…”
Get full text

Elevated levels of interleukin-12/23p40 may serve as a potential indicator of dysfunctional heart rate variability in type 2 diabetes by Wegeberg, A M, Okdahl, T, Riahi, S, Ejskjaer, N, Pociot, F, Størling, J, Brock, B, Brock, C

“…Systemic inflammatory processes plausibly contribute to the development of cardiovascular complications, causing increased morbidity and mortality in type 2…”
Get full text

Diffusion tensor imaging MR Neurography detects polyneuropathy in type 2 diabetes by Vaeggemose, M., Haakma, W., Pham, M., Ringgaard, S., Tankisi, H., Ejskjaer, N., Heiland, S., Poulsen, P.L., Andersen, H.

“…To evaluate if diffusion-tensor-imaging MR-Neurography (DTI-MRN) can detect lesions of peripheral nerves due to polyneuropathy in patients with type 2…”
Get full text

Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy—an emerging problem and solutions offered by diabetes technology by Pfützner, A., Klonoff, D., Heinemann, L., Ejskjaer, N., Pickup, J.

“…Diabetic ketoacidosis is an infrequent but life-threatening acute complication of diabetes, affecting predominantly patients with type 1 diabetes, children,…”
Get full text

Phase 2b, randomized, double‐blind 12‐week studies of TZP‐102, a ghrelin receptor agonist for diabetic gastroparesis by McCallum, R. W., Lembo, A., Esfandyari, T., Bhandari, B. R., Ejskjaer, N., Cosentino, C., Helton, N., Mondou, E., Quinn, J., Rousseau, F.

“…Background TZP‐102, a potent, oral, ghrelin receptor agonist, improved diabetic gastroparesis symptoms in Phase 2a. Methods Patients with type 1 or 2 diabetes,…”
Get full text

Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study by Charles, M., Fleischer, J., Witte, D. R., Ejskjaer, N., Borch-Johnsen, K., Lauritzen, T., Sandbaek, A.

“…Aims/hypothesis There is limited evidence on how multifactorial treatment improves outcomes of diabetes when initiated in the lead time between detection by…”
Get full text

A phase 2a, randomized, double‐blind 28‐day study of TZP‐102 a ghrelin receptor agonist for diabetic gastroparesis by Ejskjaer, N., Wo, J. M., Esfandyari, T., Mazen Jamal, M., Dimcevski, G., Tarnow, L., Malik, R. A., Hellström, P. M., Mondou, E., Quinn, J., Rousseau, F., McCallum, R. W.

“…Background  Gastroparesis causes significant morbidity and treatment options are limited. TZP‐102 a novel, macrocyclic, selective, oral ghrelin receptor…”
Get full text

Ghrelin receptor agonist (TZP‐101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis by EJSKJAER, N., VESTERGAARD, E. T., HELLSTRÖM, P. M., GORMSEN, L. C., MADSBAD, S., MADSEN, J. L., JENSEN, T. A., PEZZULLO, J. C., CHRISTIANSEN, J. S., SHAUGHNESSY, L., KOSUTIC, G.

“…Summary Background  TZP‐101 is a synthetic, selective ghrelin agonist in development for gastroparesis. Aim  To assess safety and effects of TZP‐101 in…”
Get full text

Randomised clinical trial: ghrelin agonist TZP‐101 relieves gastroparesis associated with severe nausea and vomiting – randomised clinical study subset data by Wo, J. M., Ejskjaer, N., Hellström, P. M., Malik, R. A., Pezzullo, J. C., Shaughnessy, L., Charlton, P., Kosutic, G., McCallum, R. W.

“…Aliment Pharmacol Ther 2011; 33: 679–688 Summary Background  Limited therapeutic options exist for severe gastroparesis, where severe nausea and vomiting can…”
Get full text

Safety and efficacy of ghrelin agonist TZP‐101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo‐controlled study by Ejskjaer, N., Dimcevski, G., Wo, J., Hellström, P. M., Gormsen, L. C., Sarosiek, I., Søfteland, E., Nowak, T., Pezzullo, J. C., Shaughnessy, L., Kosutic, G., Mccallum, R.

“…Background  Gastroparesis, a chronic disorder of abnormal gastric motility, is common in patients with diabetes mellitus. A synthetic, selective ghrelin…”
Get full text

Twenty years with diabetes and amputations: a retrospective population‐based cohort study by Røikjer, J., Jensen, M. H., Vestergaard, P., Sørensen, A. M., Laursen, H. V. B., Ejskjær, N.

“…Aim To investigate the trends in non‐traumatic lower limb amputation in people with and without diabetes. Methods From the Danish National Patient Register,…”
Get full text

Novel surgical treatment and gastric pathology in diabetic gastroparesis by Ejskjaer, N. T., Bradley, J. L., Buxton-Thomas, M. S., Edmonds, M. E., Howard, E. R., Purewal, T., Thomas, P. K., Watkins, P. J.

“…Summary Aims Observations are made on four Type 1 diabetic patients with the rare syndrome of intractable vomiting from confirmed gastroparesis, to determine…”
Get full text

Accelerated atrophy of lower leg and foot muscles—a follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging (MRI) by Andreassen, C. S., Jakobsen, J., Ringgaard, S., Ejskjaer, N., Andersen, H.

Get full text

Objective measurements of activity patterns in people with newly diagnosed Type 2 diabetes demonstrate a sedentary lifestyle by Cichosz, S. L., Fleischer, J., Hoeyem, P., Laugesen, E., Poulsen, P. L., Christiansen, J. S., Ejskjær, N., Hansen, T. K.

“…Aims To evaluate physical activity in people with newly diagnosed Type 2 diabetes using objective measures. Methods We analysed data from a study aimed at…”
Get full text

Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes by Ejskjaer, N., Rasmussen, M., Kamp, N., Lindholm, A., Christiansen, J. S.

“…Background:  The glycaemic control of thrice daily treatment with premixed biphasic insulin aspart (BIAsp) without other antidiabetic therapy was tested in…”
Get full text

Autoimmunity in diabetic autonomic neuropathy: does the immune system get on your nerves? by Ejskjaer, N.T., Zanone, M.M., Peakman, M.

“…Symptomatic autonomic neuropathy is a devastating occasional complication of diabetes mellitus, especially Type 1. Although the full‐blown clinical syndrome is…”
Get full text

PDB16 The Cost-Effectiveness of Empagliflozin in Type 2 Diabetes in Denmark, Incorporating Cardiovascular Outcomes by Ehlers, L.H., Lamotte, M., Monteiro, S., Sandgaard, S., Holmgaard, P., Frary, E.C., Ejskjaer, N.

Get full text

Dissociated sensory loss in diabetic autonomic neuropathy by Winkler, A. S., Ejskjaer, N., Edmonds, M., Watkins, P. J.

“…Summary Aims Clinical observation has led to the idea that there might be a distinctive form of selective sensory and autonomic neuropathy affecting patients…”
Get full text

Prevalence of autoantibodies to autonomic nervous tissue structures in Type 1 diabetes mellitus by Ejskjaer, N., Arif, S., Dodds, W., Zanone, M. M., Vergani, D., Watkins, P. J., Peakman, M.

“…Summary Aims The pathogenesis of diabetic autonomic neuropathy is multifactorial, but recent studies have suggested a link between the presence of…”
Get full text